ARWR Fundamental Analysis - ARROWHEAD PHARMACEUTICALS IN

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ARWR. ARWR was compared to 536 industry peers in the Biotechnology industry. While ARWR seems to be doing ok healthwise, there are quite some concerns on its profitability. ARWR is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ARWR has reported negative net income.

ARWR had a positive operating cash flow in the past year.

ARWR had negative earnings in each of the past 5 years.

In the past 5 years ARWR reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -10.75%, ARWR belongs to the top of the industry, outperforming 83.21% of the companies in the same industry.

The Return On Equity of ARWR (-28.42%) is better than 78.92% of its industry peers.

		Industry Rank	Sector Rank
ROA	-10.75%
ROE	-28.42%
ROIC	N/A

ROA(3y)-34.95%

ROA(5y)-28.18%

ROE(3y)-147.71%

ROE(5y)-99.18%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARWR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ARWR does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ARWR has more shares outstanding

ARWR has more shares outstanding than it did 5 years ago.

ARWR has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 2.57 indicates that ARWR is not a great score, but indicates only limited risk for bankruptcy at the moment.

ARWR has a Altman-Z score of 2.57. This is in the better half of the industry: ARWR outperforms 67.91% of its industry peers.

A Debt/Equity ratio of 0.38 indicates that ARWR is not too dependend on debt financing.

With a Debt to Equity ratio value of 0.38, ARWR is not doing good in the industry: 71.08% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.38
Debt/FCF	N/A
Altman-Z	2.57

ROIC/WACCN/A

WACC9.98%

2.3 Liquidity

A Current Ratio of 4.87 indicates that ARWR has no problem at all paying its short term obligations.

The Current ratio of ARWR (4.87) is comparable to the rest of the industry.

ARWR has a Quick Ratio of 4.87. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 4.87, ARWR is in line with its industry, outperforming 54.29% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.87
Quick Ratio	4.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.75% over the past year.

ARWR shows a strong growth in Revenue. In the last year, the Revenue has grown by 2816.21%.

Measured over the past years, ARWR shows a very negative growth in Revenue. The Revenue has been decreasing by -53.80% on average per year.

EPS 1Y (TTM)72.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.7%

Revenue 1Y (TTM)2816.21%

Revenue growth 3Y-70.5%

Revenue growth 5Y-53.8%

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ARWR will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.82% on average per year.

Based on estimates for the next years, ARWR will show a very strong growth in Revenue. The Revenue will grow by 60.01% on average per year.

EPS Next Y102.49%

EPS Next 2Y20.07%

EPS Next 3Y10.91%

EPS Next 5Y14.82%

Revenue Next Year909.09%

Revenue Next 2Y124.66%

Revenue Next 3Y64.21%

Revenue Next 5Y60.01%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARWR. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARWR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y20.07%

EPS Next 3Y10.91%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ARWR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (10/1/2025, 8:23:12 PM)

Premarket: 35.2 +0.19 (+0.54%)

35.01

+0.52 (+1.51%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-07 2025-08-07/amc

Earnings (Next)11-24 2025-11-24/amc

Inst Owners77.48%

Inst Owner Change0.81%

Ins Owners3.86%

Ins Owner Change-2.17%

Market Cap4.84B

Analysts78.1

Price Target47.47 (35.59%)

Short Float %8.98%

Short Ratio4.46

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)720.57%

Min EPS beat(2)-20.51%

Max EPS beat(2)1461.66%

EPS beat(4)1

Avg EPS beat(4)300.4%

Min EPS beat(4)-211.36%

Max EPS beat(4)1461.66%

EPS beat(8)1

Avg EPS beat(8)53.33%

EPS beat(12)2

Avg EPS beat(12)-1.35%

EPS beat(16)3

Avg EPS beat(16)3.1%

Revenue beat(2)2

Avg Revenue beat(2)847.45%

Min Revenue beat(2)14.81%

Max Revenue beat(2)1680.09%

Revenue beat(4)2

Avg Revenue beat(4)374.57%

Min Revenue beat(4)-100%

Max Revenue beat(4)1680.09%

Revenue beat(8)2

Avg Revenue beat(8)142.65%

Revenue beat(12)3

Avg Revenue beat(12)98.93%

Revenue beat(16)4

Avg Revenue beat(16)68.75%

PT rev (1m)5.77%

PT rev (3m)4.58%

EPS NQ rev (1m)-345.35%

EPS NQ rev (3m)88.45%

EPS NY rev (1m)-47.76%

EPS NY rev (3m)194.81%

Revenue NQ rev (1m)-2.99%

Revenue NQ rev (3m)-1.21%

Revenue NY rev (1m)-3.07%

Revenue NY rev (3m)-1.38%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	8.45
P/FCF	N/A
P/OCF	221.58
P/B	9.27
P/tB	9.4
EV/EBITDA	N/A

EPS(TTM)-1.27

EYN/A

EPS(NY)-2.8

Fwd EYN/A

FCF(TTM)-0.13

FCFYN/A

OCF(TTM)0.16

OCFY0.45%

SpS4.14

BVpS3.78

TBVpS3.73

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-10.75%
ROE	-28.42%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-34.95%

ROA(5y)-28.18%

ROE(3y)-147.71%

ROE(5y)-99.18%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.42

Health

		Industry Rank	Sector Rank
Debt/Equity	0.38
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	174.88%
Cap/Sales	6.89%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.87
Quick Ratio	4.87
Altman-Z	2.57

F-Score6

WACC9.98%

ROIC/WACCN/A

Cap/Depr(3y)894.03%

Cap/Depr(5y)633.96%

Cap/Sales(3y)1359.68%

Cap/Sales(5y)821.95%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)72.75%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.7%

EPS Next Y102.49%

EPS Next 2Y20.07%

EPS Next 3Y10.91%

EPS Next 5Y14.82%

Revenue 1Y (TTM)2816.21%

Revenue growth 3Y-70.5%

Revenue growth 5Y-53.8%

Sales Q2Q%N/A

Revenue Next Year909.09%

Revenue Next 2Y124.66%

Revenue Next 3Y64.21%

Revenue Next 5Y60.01%

EBIT growth 1Y80.27%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year114.94%

EBIT Next 3Y1.24%

EBIT Next 5Y10.82%

FCF growth 1Y94.86%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y111.08%

OCF growth 3YN/A

OCF growth 5YN/A

ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens